PHI density prospectively improves prostate cancer detection - Top-Institutions - MDSpire

PHI density prospectively improves prostate cancer detection

  • By

  • Carsten Stephan

  • Klaus Jung

  • Michael Lein

  • Hannah Rochow

  • Frank Friedersdorff

  • Andreas Maxeiner

  • January 20, 2021

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Urology
    • Oncology
    • Cancer Biomarkers

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urology
    • Oncology
    • Cancer Diagnostics

  • #3

    Charité – Universitätsmedizin Berlin
    Charité – Universitätsmedizin Berlin

    Berlin, Berlin

    Key Differentiators

    • Urology
    • Oncology
    • Clinical Research

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Urology
    • Oncology
    • Translational Research

  • #5

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Urology
    • Cancer Research
    • Biomarker Development

Original Source(s)

PHI density prospectively improves prostate cancer detection

  • by Carsten Stephan, Klaus Jung, Michael Lein, Hannah Rochow, Frank Friedersdorff, Andreas Maxeiner

  • January 20, 2021

Related Content

Early experience with targeted and combination biopsies in prostate cancer work-up in Denmark from 2012 to 2016

Do we need MRI in all biopsy naïve patients? A multicenter cohort analysis

Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial